Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 3,607 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent 2 Clear all

Conditions: Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Gray-Zone Lymphoma
Interventions: Polatuzumab Vedotin, Rituximab, Prednisone, Etoposide, Doxorubicin, Cyclophosphamide, Glofitamab, Multigated Acquisition Scan, Echocardiography Test, FDG-Positron Emission Tomography, Computed Tomography, Bone Marrow Biopsy, Biospecimen Collection, Bone Marrow Aspiration; Drug · Biological · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV
Interventions: Dolutegravir, Emtricitabine/Tenofovir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cancer
Interventions: Dabrafenib, Trametinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 15
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 11 more

Conditions: Adenocarcinoma of Lung
Interventions: JNJ-64041757, Nivolumab; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Baltimore, Maryland • Nashville, Tennessee • Spokane, Washington

Conditions: Coronary Artery Disease
Interventions: PROMUS Element Coronary Stent System; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Bakersfield, California • Ocala, Florida • Orlando, Florida + 11 more

Conditions: Recurrent Breast Cancer, Metastatic Breast Cancer
Interventions: Ruxolitinib, Paclitaxel; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Lymphocytic Leukemia, CLL
Interventions: Revlimid, Rituximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Soft Tissue Sarcoma
Interventions: pegylated arginine deiminase, Gemcitabine, Docetaxel, Tumor biopsy, Research blood draw; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 10 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 4
States / cities: Palo Alto, California • Santa Monica, California • St Louis, Missouri + 1 more

Conditions: Metastatic Colorectal Cancer
Interventions: Signatera ctDNA assay, pre-specified sequence of FDA-approved drugs and drug combinations; Device · Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Antibiotic Prophylaxis
Interventions: Nitrofurantoin; Drug
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Non-small Cell Lung Cancer
Interventions: NAP (Naptumomab estafenatox), Docetaxel, Obinutuzumab; Drug
Lead sponsor: NeoTX Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Daphne, Alabama • Scottsdale, Arizona • Tucson, Arizona + 8 more

Conditions: High-grade Extra Pulmonary Neuroendocrine Cancer
Interventions: All patients- TAS-102; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
Interventions: DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Chemotherapy; Biological · Radiation · Drug
Lead sponsor: DEKA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more

Conditions: Advanced Solid Tumor
Interventions: RP3, Nivolumab; Biological
Lead sponsor: Replimune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Iowa City, Iowa • Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Smoking Cessation
Interventions: Contingency management, Nicotine replacement therapy, Varenicline, Additional behavioral support; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer, Locally Advanced Breast Cancer
Interventions: Palazestrant, Ribociclib, Alpelisib, Everolimus, Atirmociclib; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 14
States / cities: Gilbert, Arizona • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Melanoma, Unresectable Melanoma
Interventions: Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Ozuriftamab Vedotin, Pembrolizumab, Evalstotug (BA3071), Cetuximab; Biological
Lead sponsor: BioAtla, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 7
States / cities: Los Angeles, California • Newark, Delaware • Chicago, Illinois + 4 more

Conditions: Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions: Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid, Icatibant, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Colorectal Cancer
Interventions: Imprime PGG + cetuximab, Cetuximab; Biological · Drug
Lead sponsor: HiberCell, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 44
States / cities: Florence, Alabama • Bentonville, Arkansas • Anaheim, California + 38 more

Conditions: Acute Undifferentiated Leukemia, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, L1 Adult Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Adult Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: allopurinol, cyclophosphamide, daunorubicin hydrochloride, vincristine sulfate, dexamethasone, asparaginase, filgrastim, imatinib mesylate, methotrexate, cytarabine, trimethoprim-sulfamethoxazole, mercaptopurine, leucovorin calcium, alemtuzumab, acyclovir, laboratory biomarker analysis, pharmacological study; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 15 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: HIV LFn-p24; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Metastatic Castrate-Resistant Prostate Cancer
Interventions: Alobresib, Enzalutamide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy; Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial

Use of Prophylactic Antibiotics Prior to OnabotulinumtoxinA

NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

TAS-102 in Extrapulmonary Neuroendocrine Carcinoma

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

A Smoking Cessation Intervention for Yale Dining Employees

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach